Indivior stock trades below fair value as latest earnings beat expectations
Published on 08/29/2026 at 11:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Indivior PLC (GB00BYZ0C031) stock is drawing attention on August 29, 2026, as recent market data and earnings figures show the addiction-treatment specialist delivering stronger-than-expected results while its valuation still sits below some fair value estimates.
Earnings beat and revenue growth
According to a real-time market overview updated on August 28, 2026, Indivior PLC reported earnings per share of $0.32 in its latest quarter, versus an analyst estimate of $0.22, representing a positive surprise of 43.82 percent in the period. The same dataset indicates that revenue for the quarter came in at $298.00 million, compared with an estimate of $259.78 million, meaning reported sales exceeded expectations by $38.22 million as the company continues to expand its presence in addiction treatment markets. In addition, net income for the latest quarter was $20.00 million, which marked a significant improvement over the prior quarter’s $4.00 million, a 400.00 percent quarter-over-quarter increase that underscores the impact of operating leverage and cost control.
In parallel with these fundamental data points, one valuation-focused analysis highlighted that Indivior Pharmaceuticals closed at $35.30 per share in a recent US trading session, while the same assessment framed a fair value level at $53.00. This implies that the shares traded $17.70 below that estimated fair value, signaling potential upside if the company continues to deliver earnings surprises and revenue outperformance.
Market reaction and trading metrics
A real-time quote snapshot for Indivior PLC indicates that the current price of INDV is $9.78 per share in its latest indicated trading, with the share price up 2.99 percent over the last 24 hours as of August 28, 2026, reflecting a modest positive reaction to the recent earnings beat. The same data show that the shares have risen 0.71 percent over the past week, adding a short-term gain, while the monthly variation has been a stronger increase of 26.65 percent, suggesting that investors have steadily reassessed the company’s prospects in light of its operational performance and sector developments. Over the last year, the dataset reports that Indivior PLC’s shares have declined 53.91 percent, a reminder that despite the recent rebound, longer-term holders have faced material volatility and drawdowns.
Another market-coverage source lists Indivior Pharmaceuticals, Inc. at a price of $34.70 in a related US listing context, coupled with a market capitalization of $4.095 billion, placing the company firmly in the mid-cap specialty and generic drug manufacturers segment. In that framework, the share price performance is tracked alongside sector peers, providing investors with a way to compare Indivior’s valuation and momentum within the broader specialty pharmaceuticals landscape.
Consensus view and growth expectations
A growth-investor-oriented analysis notes that the consensus estimate for Indivior’s current year earnings has increased 2.7 percent over the past month, indicating that analysts have revised their expectations higher following the latest quarterly report and updated guidance signals. This upward move in the consensus forecast aligns with the company’s demonstrated ability to beat revenue and earnings estimates, as shown by the reported $0.32 per-share earnings versus the $0.22 expectation and the $298.00 million in revenue versus the $259.78 million forecast in the most recent quarter.
The same market-data compilation indicates that earnings per share expected for the next quarter are $0.23, while revenue is projected at $240.60 million. These forward-looking figures suggest that, even after a strong quarter, analysts anticipate some normalization in quarterly sales and profits, yet still see the company maintaining a solid baseline of profitability driven by its core addiction-treatment franchise and related therapeutic offerings. For investors, the combination of rising consensus estimates and a share price that trades below some fair value models can present an interesting setup for those willing to evaluate the underlying risk profile and regulatory environment around opioid and addiction therapies.
Business profile and key product context
Indivior PLC focuses on the development and commercialization of medications aimed at treating opioid use disorder and related addictions, positioning the company within the drug manufacturers specialty and generic category where regulatory oversight and clinical efficacy play critical roles in long-term performance. Its portfolio is centered on therapies designed to help patients manage dependence and withdrawal, and the firm’s business model relies on both branded formulations and carefully managed generic competition.
Within this framework, the company’s progress in growing quarterly revenue to $298.00 million while beating consensus expectations by a wide margin in its latest reported period underscores the ongoing demand for effective addiction-treatment solutions. As healthcare systems worldwide continue to address opioid misuse, pricing dynamics, reimbursement decisions, and clinical adoption trends will remain central to how Indivior’s products translate into sustained sales and earnings growth.
Shares and recent valuation markers
From a trading perspective, the recent indication that Indivior PLC’s shares are priced at $9.78 with a 2.99 percent 24-hour gain as of August 28, 2026, combined with a one-month increase of 26.65 percent, points to a phase of recovery following the longer-term 53.91 percent decline over the last year. This multi-period performance profile shows that while the stock has been volatile and has historically moved lower over a twelve-month window, more recent momentum has turned positive as earnings surprises and analyst estimate revisions support sentiment.
In the related US market context, the quoted price of $34.70 for Indivior Pharmaceuticals, Inc. and the associated $4.095 billion market capitalization offer another angle for investors assessing valuation. When compared with the $53.00 fair value estimate referenced in one analysis, the $34.70 share price implies that the US listing trades significantly below that model’s assessment of intrinsic worth, a gap that may close or widen depending on how future quarterly revenue and earnings figures stack up against both consensus forecasts and regulatory developments in the addiction-treatment space.
Fact box: Indivior PLC key data
Company: Indivior PLC
ISIN: GB00BYZ0C031
Ticker: INDV
Exchange: Nasdaq and primary listing in its home market context
Sector / Industry: Drug manufacturers specialty and generic
Latest quarterly earnings per share: $0.32, versus a consensus estimate of $0.22, a positive surprise of 43.82 percent in the period ended in the most recent quarter reported as of August 28, 2026. Latest quarterly revenue: $298.00 million, compared with an estimate of $259.78 million, exceeding expectations by $38.22 million and highlighting solid demand for the company’s addiction-treatment portfolio. Latest quarterly net income: $20.00 million, versus $4.00 million in the preceding quarter, a 400.00 percent quarter-over-quarter increase that reflects improved profitability dynamics.
Current indicated price for Indivior PLC’s shares: $9.78, up 2.99 percent over the last 24 hours as of August 28, 2026, with a weekly gain of 0.71 percent, a monthly gain of 26.65 percent, and a twelve-month decline of 53.91 percent, according to real-time market data. Related US listing price for Indivior Pharmaceuticals, Inc.: $34.70, with a reported market capitalization of $4.095 billion among drug manufacturers specializing in specialty and generic products, in the context of August 29, 2026 coverage.
